Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tizanidine
Drug ID BADD_D02230
Description Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury [T574]. It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
Indications and Usage Tizanidine is indicated for the relief of muscle spasticity, which can interfere with daily activities. The general recommendation is to reserve tizanidine use for periods of time when there is a particular need for relief, as it has a short duration of action [FDA label, F4471].
Marketing Status approved; investigational
ATC Code M03BX02
DrugBank ID DB00697
KEGG ID D08611
MeSH ID C023754
PubChem ID 5487
TTD Drug ID D01MDT
NDC Product Code 72789-325; 35356-662; 50090-0840; 51655-740; 53002-1418; 57664-502; 60760-694; 70771-1335; 72578-096; 61919-221; 63187-009; 63187-910; 63629-8533; 68084-645; 29300-168; 29300-169; 42291-809; 55111-180; 60760-263; 63629-2371; 71610-228; 60760-505; 63187-493; 63187-673; 68084-775; 70518-3658; 71610-451; 0615-8468; 72578-097; 0904-6418; 43063-868; 60505-0251; 60760-782; 67877-614; 68071-5268; 70518-2210; 70771-1336; 71205-311; 71335-1016; 71335-1799; 0615-8360; 76420-228; 55111-179; 60505-0252; 60760-719; 63629-3209; 67877-613; 68788-7782; 70518-3181; 71610-162; 71610-455; 42291-808; 50090-0841; 63187-145; 63629-1673; 67296-1599; 70518-0133; 70518-1439; 70518-3112; 71610-167; 0615-8274; 0615-8469; 72789-326; 16714-172; 50090-0811; 50090-5767; 51655-603; 53002-1437; 68071-3440; 70518-0573; 72789-327; 76420-229; 43063-455; 55154-7287; 57664-503; 63629-2370; 68788-7781; 68788-7991; 16714-171; 71335-0914; 43353-167; 50268-759; 50268-760
UNII 6AI06C00GW
Synonyms tizanidine | 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1,3-benzothiadiazole | Zanaflex | tizanidine hydrochloride | tizanidine monohydrochloride | DS 103-282 | Sirdalud
Chemical Information
Molecular Formula C9H8ClN5S
CAS Registry Number 51322-75-9
SMILES C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoproteinaemia14.10.01.003; 09.01.02.004--Not Available
Hypotension24.06.03.0020.001040%
Hypothyroidism14.11.01.012; 05.02.03.001--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site erythema08.02.03.001; 23.03.06.015; 12.07.03.0010.000052%Not Available
Injection site pain12.07.03.011; 08.02.03.0100.000115%Not Available
Insomnia19.02.01.002; 17.15.03.0020.000408%
Intestinal obstruction07.13.01.002--Not Available
Iritis10.02.01.022; 06.04.03.002--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000052%Not Available
Keratitis06.04.02.002--
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.000209%
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Liver disorder09.01.08.001--Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.000105%Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.0040.000052%Not Available
Mental disability26.01.01.001--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.0030.000209%Not Available
Mood swings19.04.03.001--Not Available
Movement disorder17.01.02.0100.000052%Not Available
Multiple sclerosis17.16.01.001; 10.04.10.0080.000052%Not Available
Muscle spasms15.05.03.0040.000460%
Muscle twitching15.05.03.005--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene